Market Cap 10.45B
Revenue (ttm) 3.22B
Net Income (ttm) 348.90M
EPS (ttm) N/A
PE Ratio 26.65
Forward PE 12.71
Profit Margin 10.83%
Debt to Equity Ratio 0.00
Volume 1,803,700
Avg Vol 1,968,614
Day's Range N/A - N/A
Shares Out 193.28M
Stochastic %K 63%
Beta 0.23
Analysts Strong Sell
Price Target $88.38

Company Profile

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic pep...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 506 6700
Address:
770 Lindaro Street, San Rafael, United States
Bobear12
Bobear12 May. 23 at 9:40 PM
$BMRN Galectin Therapeutics (NASDAQ: GALT) is presenting new clinical analyses of its Phase 2b NAVIGATE trial for its lead drug, belapectin, at the EASL Congress. The presentations at the European Association for the Study of the Liver focus on preventing esophageal varices and improving liver biomarkers in patients with MASH cirrhosis.
1 · Reply
DairyQueen505
DairyQueen505 May. 22 at 4:57 PM
$BMRN always dumps on Fridays
1 · Reply
pnvoss
pnvoss May. 22 at 7:16 AM
$BMRN $SPY on watch will analyze when I get home
1 · Reply
Jstr22
Jstr22 May. 21 at 5:36 PM
$BMRN Been Holding since the end of last summer. Market is finally waking up to the value here-
1 · Reply
OpenOutcrier
OpenOutcrier May. 21 at 12:40 PM
$BMRN (+0.1% pre) BioMarin positive hypochondroplasia trial data https://ooc.bz/l/103147
0 · Reply
DairyQueen505
DairyQueen505 May. 21 at 11:01 AM
$BMRN real question is whether this excellent news will actually move the stock.
1 · Reply
notreload_ai
notreload_ai May. 21 at 10:47 AM
$BMRN VOXZOGO improved growth in children with hypochondroplasia, showing strong trial results and good safety. https://notreload.xyz/xy/voxzogo-delivers-positive-phase-3-results-in-hypochondroplasia/
0 · Reply
AuStocks
AuStocks May. 21 at 2:15 AM
$BMRN I just found this company and wow. The financials are incredible. These are the type of companies that survive an economic downturn
2 · Reply
explover
explover May. 20 at 8:53 PM
$BMRN wow, great hypochondroplasia results, sNDA in the bag, additional >$800M high-margin peak annual revenue in a greenfield market
1 · Reply
Rambit
Rambit May. 20 at 8:41 PM
$BMRN https://www.prnewswire.com/news-releases/biomarin-announces-positive-phase-3-pivotal-study-results-for-voxzogo-vosoritide-in-children-with-hypochondroplasia-302778176.html
0 · Reply
Latest News on BMRN
BioMarin price target lowered to $111 from $116 at Canaccord

2026-05-22T10:40:10.000Z - 5 days ago

BioMarin price target lowered to $111 from $116 at Canaccord


BioMarin price target lowered to $80 from $85 at BofA

2026-05-19T10:35:49.000Z - 8 days ago

BioMarin price target lowered to $80 from $85 at BofA


BioMarin initiated with a Buy at Citi

2026-05-18T20:21:16.000Z - 8 days ago

BioMarin initiated with a Buy at Citi


BioMarin price target lowered to $62 from $64 at Leerink

2026-05-18T18:50:49.000Z - 8 days ago

BioMarin price target lowered to $62 from $64 at Leerink


BioMarin reinstated with a Neutral at Goldman Sachs

2026-05-11T09:10:08.000Z - 16 days ago

BioMarin reinstated with a Neutral at Goldman Sachs


BioMarin price target raised to $116 from $104 at Canaccord

2026-05-07T17:03:35.000Z - 19 days ago

BioMarin price target raised to $116 from $104 at Canaccord


BioMarin price target lowered to $82 from $94 at Bernstein

2026-05-05T10:49:38.000Z - 22 days ago

BioMarin price target lowered to $82 from $94 at Bernstein


BioMarin Pharmaceutical Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 22 days ago

BioMarin Pharmaceutical Earnings Call Transcript: Q1 2026


BioMarin Pharmaceutical Slides: Q1 2026

May 4, 2026, 4:30 PM EDT - 22 days ago

BioMarin Pharmaceutical Slides: Q1 2026


BioMarin Pharmaceutical Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 22 days ago

BioMarin Pharmaceutical Earnings release: Q1 2026


BioMarin Pharmaceutical Quarterly report: Q1 2026

May 4, 2026, 4:30 PM EDT - 22 days ago

BioMarin Pharmaceutical Quarterly report: Q1 2026


BioMarin announces new research from studies of Voxzogo

2026-05-03T17:50:33.000Z - 23 days ago

BioMarin announces new research from studies of Voxzogo


BioMarin Completes Acquisition of Amicus Therapeutics

Apr 27, 2026, 8:44 AM EDT - 4 weeks ago

BioMarin Completes Acquisition of Amicus Therapeutics


BioMarin Announces Board Leadership Transition

Apr 21, 2026, 4:23 PM EDT - 5 weeks ago

BioMarin Announces Board Leadership Transition


BioMarin Pharmaceutical Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

BioMarin Pharmaceutical Proxy statement: Proxy filing


BioMarin Pharmaceutical Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

BioMarin Pharmaceutical Proxy statement: Proxy filing


BioMarin stops mid-stage trials of bone disorder treatment

Mar 16, 2026, 9:40 AM EDT - 2 months ago

BioMarin stops mid-stage trials of bone disorder treatment


BioMarin Pharmaceutical Earnings Call Transcript: Q4 2025

Feb 23, 2026, 4:30 PM EST - 3 months ago

BioMarin Pharmaceutical Earnings Call Transcript: Q4 2025


BioMarin Pharmaceutical Annual report: Q4 2025

Feb 23, 2026, 4:30 PM EST - 3 months ago

BioMarin Pharmaceutical Annual report: Q4 2025


BioMarin Pharmaceutical Earnings release: Q4 2025

Feb 23, 2026, 4:30 PM EST - 3 months ago

BioMarin Pharmaceutical Earnings release: Q4 2025


BioMarin Pharmaceutical Slides: Q4 2025

Feb 23, 2026, 4:30 PM EST - 3 months ago

BioMarin Pharmaceutical Slides: Q4 2025


BioMarin Announces Closing of Private Offering of Senior Notes

Feb 12, 2026, 4:05 PM EST - 3 months ago

BioMarin Announces Closing of Private Offering of Senior Notes


Veeva and BioMarin Form Long-Term Strategic Partnership

Jan 8, 2026, 8:30 AM EST - 4 months ago

Veeva and BioMarin Form Long-Term Strategic Partnership

VEEV


BioMarin Pharmaceutical Transcript: M&A Announcement

Dec 19, 2025, 8:15 AM EST - 5 months ago

BioMarin Pharmaceutical Transcript: M&A Announcement


BioMarin Pharmaceutical Press release: M&A Announcement

Dec 19, 2025, 8:15 AM EST - 5 months ago

BioMarin Pharmaceutical Press release: M&A Announcement


BioMarin Pharmaceutical Slides: M&A Announcement

Dec 19, 2025, 8:15 AM EST - 5 months ago

BioMarin Pharmaceutical Slides: M&A Announcement


BioMarin to Buy Amicus Therapeutics for $4.8 Billion

Dec 19, 2025, 8:13 AM EST - 5 months ago

BioMarin to Buy Amicus Therapeutics for $4.8 Billion

FOLD


BioMarin to acquire Amicus Therapeutics for $4.8 Billion

Dec 19, 2025, 7:56 AM EST - 5 months ago

BioMarin to acquire Amicus Therapeutics for $4.8 Billion

FOLD


BioMarin Pharma plans to divest struggling gene therapy

Oct 27, 2025, 6:34 PM EDT - 7 months ago

BioMarin Pharma plans to divest struggling gene therapy


BioMarin Pharmaceutical Earnings Call Transcript: Q3 2025

Oct 27, 2025, 4:30 PM EDT - 7 months ago

BioMarin Pharmaceutical Earnings Call Transcript: Q3 2025


BioMarin Pharmaceutical Quarterly report: Q3 2025

Oct 27, 2025, 4:30 PM EDT - 7 months ago

BioMarin Pharmaceutical Quarterly report: Q3 2025


BioMarin Pharmaceutical Earnings release: Q3 2025

Oct 27, 2025, 4:30 PM EDT - 7 months ago

BioMarin Pharmaceutical Earnings release: Q3 2025


BioMarin Pharmaceutical Slides: Q3 2025

Oct 27, 2025, 4:30 PM EDT - 7 months ago

BioMarin Pharmaceutical Slides: Q3 2025


BioMarin to Participate in Upcoming Investor Conferences

Aug 27, 2025, 9:00 AM EDT - 9 months ago

BioMarin to Participate in Upcoming Investor Conferences


BioMarin Pharmaceutical Earnings Call Transcript: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 10 months ago

BioMarin Pharmaceutical Earnings Call Transcript: Q2 2025


BioMarin Pharmaceutical Quarterly report: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 10 months ago

BioMarin Pharmaceutical Quarterly report: Q2 2025


BioMarin Pharmaceutical Earnings release: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 10 months ago

BioMarin Pharmaceutical Earnings release: Q2 2025


BioMarin Pharmaceutical Slides: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 10 months ago

BioMarin Pharmaceutical Slides: Q2 2025


BioMarin Announces Completion of Acquisition of Inozyme

Jul 1, 2025, 8:45 AM EDT - 11 months ago

BioMarin Announces Completion of Acquisition of Inozyme

INZY


BioMarin Pharmaceutical Transcript: M&A Announcement

May 16, 2025, 8:45 AM EDT - 1 year ago

BioMarin Pharmaceutical Transcript: M&A Announcement


BioMarin Pharmaceutical Press release: M&A Announcement

May 16, 2025, 8:45 AM EDT - 1 year ago

BioMarin Pharmaceutical Press release: M&A Announcement


BioMarin Pharmaceutical Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

BioMarin Pharmaceutical Earnings Call Transcript: Q1 2025


BioMarin Pharmaceutical Quarterly report: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

BioMarin Pharmaceutical Quarterly report: Q1 2025


BioMarin Pharmaceutical Earnings release: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

BioMarin Pharmaceutical Earnings release: Q1 2025


BioMarin Pharmaceutical Slides: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

BioMarin Pharmaceutical Slides: Q1 2025


BioMarin Pharmaceutical Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

BioMarin Pharmaceutical Proxy statement: Proxy Filing


BioMarin Pharmaceutical Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

BioMarin Pharmaceutical Proxy statement: Proxy Filing


Bobear12
Bobear12 May. 23 at 9:40 PM
$BMRN Galectin Therapeutics (NASDAQ: GALT) is presenting new clinical analyses of its Phase 2b NAVIGATE trial for its lead drug, belapectin, at the EASL Congress. The presentations at the European Association for the Study of the Liver focus on preventing esophageal varices and improving liver biomarkers in patients with MASH cirrhosis.
1 · Reply
DairyQueen505
DairyQueen505 May. 22 at 4:57 PM
$BMRN always dumps on Fridays
1 · Reply
pnvoss
pnvoss May. 22 at 7:16 AM
$BMRN $SPY on watch will analyze when I get home
1 · Reply
Jstr22
Jstr22 May. 21 at 5:36 PM
$BMRN Been Holding since the end of last summer. Market is finally waking up to the value here-
1 · Reply
OpenOutcrier
OpenOutcrier May. 21 at 12:40 PM
$BMRN (+0.1% pre) BioMarin positive hypochondroplasia trial data https://ooc.bz/l/103147
0 · Reply
DairyQueen505
DairyQueen505 May. 21 at 11:01 AM
$BMRN real question is whether this excellent news will actually move the stock.
1 · Reply
notreload_ai
notreload_ai May. 21 at 10:47 AM
$BMRN VOXZOGO improved growth in children with hypochondroplasia, showing strong trial results and good safety. https://notreload.xyz/xy/voxzogo-delivers-positive-phase-3-results-in-hypochondroplasia/
0 · Reply
AuStocks
AuStocks May. 21 at 2:15 AM
$BMRN I just found this company and wow. The financials are incredible. These are the type of companies that survive an economic downturn
2 · Reply
explover
explover May. 20 at 8:53 PM
$BMRN wow, great hypochondroplasia results, sNDA in the bag, additional >$800M high-margin peak annual revenue in a greenfield market
1 · Reply
Rambit
Rambit May. 20 at 8:41 PM
$BMRN https://www.prnewswire.com/news-releases/biomarin-announces-positive-phase-3-pivotal-study-results-for-voxzogo-vosoritide-in-children-with-hypochondroplasia-302778176.html
0 · Reply
DairyQueen505
DairyQueen505 May. 20 at 8:38 PM
$BMRN huge news. This should pump tomorrow.
0 · Reply
DairyQueen505
DairyQueen505 May. 20 at 7:23 PM
$BMRN Time for the daily dump.
0 · Reply
Y42
Y42 May. 20 at 1:46 PM
$BMRN hardly. The probability to receive good news* about it is above 90%, roughly speaking.
1 · Reply
LongsInvestments2
LongsInvestments2 May. 19 at 1:48 AM
$BMRN dam...I thought it was the Tom Lee stock
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 19 at 1:24 AM
1 reason we still like $NBIX after an 18% gain over the last month is because NBIX still trades at a lower multiple of analyst consensus revenue estimates than peers projected to generate at least $10B in revenues over the next 5 years (attached). Of course a correction in the $XBI will affect all peers, but remember NBIX & SLNO generated 97% gross margins (higher than these peers). $BMRN enterprise value does not reflect closing the Amicus acquisition. While BMRN's multiple is low, so is its gross margin v these peers. $ALKS completed the acquisition of Avadel in February $INSM is off 50% the last 6 months. As always, this is not investment advice. We're merely sharing analysis
0 · Reply
DairyQueen505
DairyQueen505 May. 19 at 1:22 AM
$BMRN Ugly chart. If bad news on Vox Hyperchondroplasia study could see $30 stock.
2 · Reply
Edgebell
Edgebell May. 19 at 1:08 AM
$BMRN edgebell score. Not financial advice. See link in bio for more info
0 · Reply
giuseppe8469
giuseppe8469 May. 19 at 12:39 AM
$BMRN they convert .26 to every dollar they make to fcf this is a short term shakeout I will be loading alot more on this dip easy money 💴 tghat fcf can be used buybacks , dividends ,debt reduction, reinvstement , rev 13% year over year growth this should be 85$ stock and will be in time
0 · Reply
DairyQueen505
DairyQueen505 May. 18 at 6:22 PM
$BMRN melt down. RIP
0 · Reply
StockBraker
StockBraker May. 18 at 4:41 PM
$BMRN BioMarin Pharmaceutical announces results from the pivotal Phase 3 ENERGY 3 trial evaluating BMN 401 in children aged 1-12 with ENPP1 deficiency, a rare, serious and progressive genetic condition ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency. Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration, one of the study''s co-primary endpoints; however, no improvement was observed in Radiographic Global Impression of Change (RGI-C) scores, the study''s other co-primary endpoint and an important clinical measure of change in rickets severity. Company is evaluating data to determine next steps.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck May. 18 at 3:57 PM
0 · Reply
Cantstandzya
Cantstandzya May. 18 at 12:49 PM
$BMRN by all metrics this should be moving up, especially in this market. it's tough watching micron and Intel going 10x while this 💩goes lower .
0 · Reply